Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Karus Therapeutics Announces Collaboration with Babraham Institute

Published: Tuesday, December 18, 2012
Last Updated: Monday, December 17, 2012
Bookmark and Share
Collaboration to explore PI3 kinase inhibitors in the treatment of inflammatory diseases.

Karus Therapeutics has announced that it has entered into a collaboration with the Babraham Institute (Cambridge, UK), to further characterize novel treatments for inflammatory diseases through the regulation of phosphatidylinositol-3-kinase (PI3K) - a family of enzymes important to immune cell function.

This collaboration will be led by Dr Stephen Shuttleworth, Chief Scientific Officer of Karus.

He will be working closely with the Babraham team headed by Dr Len Stephens and Dr Phillip Hawkins to further investigate PI3K signaling and the immune response and, in particular, the role of the different isoforms of the PI3K catalytic subunit p110 on neutrophil cell function.

Under the terms of the agreement, the team will further interrogate the mechanism by which Karus Therapeutics’ PI3K-p110 beta and PI3K-p110 delta inhibitors impact on neutrophil function and immune responses, with the aim of developing more effective treatments for inflammatory diseases such as rheumatoid arthritis. Financial terms were not disclosed.

Dr Shuttleworth said: “Dr Stephens and Dr Hawkins are key opinion leaders in the area of PI3K biology, notably in the context of neutrophil function. They have recently made key discoveries that are having a significant impact on the design of isoform-selective PI3K inhibitors for the treatment of chronic immune disorders. I have successfully collaborated with the Babraham team in the past and am delighted to be working with them again at Karus.”

Dr Hawkins added, “We have already shown in vivo that targeting of PI3K-p110 beta and PI3K-p110 delta is an effective way to treat rheumatoid arthritis in small animal models. By working with Karus, we gain unique access to scientific leadership in the field of PI3K inhibitor design and development. We look forward to working with Stephen and his team to convert scientific discovery into medical breakthrough.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Switch Lets Salmonella Fight, Evade Immune System
Researchers at the University of Illinois at Chicago have discovered a molecular regulator that allows salmonella bacteria to switch from actively causing disease to lurking in a chronic but asymptomatic state called a biofilm.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Neural Networks Adapt to the Presence of a Toxic HIV Protein
HIV-associated neurocognitive disorders (HAND) afflict approximately half of HIV infected patients.
HIV Protein Manipulates Hundreds of Human Genes
Findings search for new or improved treatments for patients with AIDS.
Breaking the Brain’s Garbage Disposal
The children’s ataxia gene problem turned out to be not such a big deal genetically — it was such a slight mutation that it barely changed the way the cells made the protein.
Flesh-Eating Bacteria Work Together
Scientists recently discovered different strains of deadly flesh-eating bacteria working together to spread infection and they now have a better understanding of the role of the toxins they produce. The discovery could change how the illness and other diseases are treated.
Utilizing Antibodies from Ebola Survivors
A collaborative team from The University of Texas Medical Branch at Galveston, Vanderbilt University, The Scripps Research Institute and Integral Molecular Inc. have learned that antibodies in the blood of people who have survived a strain of the Ebola virus can kill various types of Ebola.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!